Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

NCT04307186 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Central Nervous System Pathology

Interventions

DRUG: Gadoquatrane (BAY1747846)
DRUG: Gadobutrol (Gadovist/Gadavist)

Sponsor

Bayer